3-D QSAR Studies on Histone Deacetylase Inhibitors. A GOLPE/GRID Approach on Different Series of Compounds

Docking simulation and three-dimensional quantitative structure-activity relationships (3D-QSARs) analyses were conducted on four series of HDAC inhibitors. The studies were performed using the GRID/GOLPE combination using structure-based alignment. Twelve 3-D QSAR models were derived and discussed. Compared to previous studies on similar inhibitors, the present 3-D QSAR investigation proved to be of higher statistical value, displaying for the best global model r2, q2, and cross-validated SDEP values of 0.94, 0.83, and 0.41, respectively. A comparison of the 3-D QSAR maps with the structural features of the binding site showed good correlation. The results of 3D-QSAR and docking studies validated each other and provided insight into the structural requirements for anti-HDAC activity. To our knowledge this is the first 3-D QSAR application on a broad molecular diversity training set of HDACIs.

[1]  G. Chang,et al.  Macromodel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanics , 1990 .

[2]  R A Rifkind,et al.  Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. , 2000, Cancer research.

[3]  Robert Brown,et al.  Epigenomics and epigenetic therapy of cancer. , 2002, Trends in molecular medicine.

[4]  G. Brosch,et al.  Purification and characterization of a high molecular weight histone deacetylase complex (HD2) of maize embryos. , 1996, Biochemistry.

[5]  Silvio Massa,et al.  3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures. , 2003, Journal of medicinal chemistry.

[6]  D. Doenecke,et al.  Acetylation of histones in nucleosomes , 1982, Molecular and Cellular Biochemistry.

[7]  Manfred Jung,et al.  Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells. , 2002, Journal of medicinal chemistry.

[8]  A. Mai,et al.  Exploring the connection unit in the HDAC inhibitor pharmacophore model: novel uracil-based hydroxamates. , 2005, Bioorganic & medicinal chemistry letters.

[9]  M. Grunstein,et al.  Extremely conserved histone H4 N terminus is dispensable for growth but essential for repressing the silent mating loci in yeast , 1988, Cell.

[10]  G Brosch,et al.  Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. , 1999, Journal of medicinal chemistry.

[11]  T. Theophanides,et al.  Molecular modeling of azole antifungal agents active against Candida albicans. 1. A comparative molecular field analysis study. , 1996, Journal of medicinal chemistry.

[12]  P. Marks,et al.  Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.

[13]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[14]  Leming Shi,et al.  Quantitative structure-activity relationship study of histone deacetylase inhibitors. , 2004, Current medicinal chemistry. Anti-cancer agents.

[15]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[16]  Matthew Clark,et al.  The Probability of Chance Correlation Using Partial Least Squares (PLS) , 1993 .

[17]  B. Skagerberg,et al.  Predictive ability of regression models. Part I: Standard deviation of prediction errors (SDEP) , 1992 .

[18]  L. Altucci,et al.  Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. , 2005, Journal of medicinal chemistry.

[19]  Jasper Rine,et al.  The establishment, inheritance, and function of silenced chromatin in Saccharomyces cerevisiae. , 2003, Annual review of biochemistry.

[20]  Haruki Nakamura,et al.  Announcing the worldwide Protein Data Bank , 2003, Nature Structural Biology.

[21]  S. Wold,et al.  PLS: Partial Least Squares Projections to Latent Structures , 1993 .

[22]  Peter A. Kollman,et al.  AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules , 1995 .

[23]  Susan Jones,et al.  Histone Deacetylase Inhibitors as Potential Anti-Skin Cancer Agents 1 , 1999 .

[24]  V. L. Greenberg,et al.  Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells. , 2001, Thyroid : official journal of the American Thyroid Association.

[25]  B. Tycko,et al.  Epigenetic gene silencing in cancer. , 2000, The Journal of clinical investigation.

[26]  G. Marshall,et al.  Antimycobacterial pyrroles: synthesis, anti-Mycobacterium tuberculosis activity and QSAR studies. , 2000, Bioorganic & medicinal chemistry.

[27]  Minoru Yoshida,et al.  [Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A]. , 1990, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[28]  M. Grunstein,et al.  HDA1 and HDA3 Are Components of a Yeast Histone Deacetylase (HDA) Complex* , 1996, The Journal of Biological Chemistry.

[29]  Yan-shen Guo,et al.  Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses. , 2005, Bioorganic & medicinal chemistry.

[30]  G. Marshall,et al.  Design, synthesis and QSAR studies on N-aryl heteroarylisopropanolamines, a new class of non-peptidic HIV-1 protease inhibitors. , 2002, Bioorganic & medicinal chemistry.

[31]  Silvio Massa,et al.  Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation. , 2002, Journal of medicinal chemistry.

[32]  G. Cruciani,et al.  Comparative molecular field analysis using GRID force-field and GOLPE variable selection methods in a study of inhibitors of glycogen phosphorylase b. , 1994, Journal of medicinal chemistry.

[33]  M. Jung,et al.  Inhibitors of histone deacetylase as new anticancer agents. , 2001, Current medicinal chemistry.

[34]  J. M. Sherman,et al.  The SIR2 gene family, conserved from bacteria to humans, functions in silencing, cell cycle progression, and chromosome stability. , 1995, Genes & development.

[35]  Ivan V. Gregoretti,et al.  Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. , 2004, Journal of molecular biology.

[36]  L. Magnaghi-Jaulin,et al.  Histone acetylation and the control of the cell cycle. , 2000, Progress in cell cycle research.

[37]  P. Marks,et al.  Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. , 2001, Blood cells, molecules & diseases.

[38]  R. Brachmann,et al.  Chromatin Remodeling and Cancer , 2003, Cancer biology & therapy.

[39]  S. Archer,et al.  Histone acetylation and cancer. , 1999, Current opinion in genetics & development.

[40]  P. Laird.  Cancer epigenetics. , 2005, Human molecular genetics.

[41]  Histone deacetylase , 1993, FEBS letters.

[42]  M. Grunstein,et al.  HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes that regulate silencing and transcription. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[43]  A. Mai,et al.  Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A. , 2003, Journal of medicinal chemistry.

[44]  K. Struhl,et al.  The histone deacetylase RPD3 counteracts genomic silencing in Drosophila and yeast , 1996, Nature.

[45]  Silvio Massa,et al.  Histone deacetylation in epigenetics: An attractive target for anticancer therapy , 2005, Medicinal research reviews.

[46]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[47]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.

[48]  G. Cruciani,et al.  Generating Optimal Linear PLS Estimations (GOLPE): An Advanced Chemometric Tool for Handling 3D‐QSAR Problems , 1993 .

[49]  B. Kennedy,et al.  Localization of Sir2p: the nucleolus as a compartment for silent information regulators , 1997, The EMBO journal.

[50]  P. Loidl.  Histone acetylation: facts and questions , 1994, Chromosoma.